Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers

BACKGROUND: Peginterferon beta-1a administered every 2 weeks via subcutaneous (SC) injection is approved to treat adult patients with relapsing-remitting multiple sclerosis (RRMS) and relapsing forms of multiple sclerosis (RMS). However, associated injection site reactions (ISRs) can lead to treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yuan, Chen, Kun, Ramia, Nancy, Sahu, Sangeeta, Kumar, Achint, Naylor, Maria L., Zhu, Li, Naik, Himanshu, Butts, Cherié L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883310/
https://www.ncbi.nlm.nih.gov/pubmed/33628334
http://dx.doi.org/10.1177/1756286420975227

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7883310/
https://www.ncbi.nlm.nih.gov/pubmed/33628334
http://dx.doi.org/10.1177/1756286420975227

Ejemplares similares